Related references
Note: Only part of the references are listed.Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry
Takayuki Iwamoto et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
Joanne S. L. Lim et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Sex Hormone Levels and Risks of Estrogen Receptor-Negative and Estrogen Receptor-Positive Breast Cancers
Ghada N. Farhat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients
Ron H. N. van Schaik et al.
PHARMACOGENOMICS (2011)
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
Jennifer Gjerde et al.
BMC CANCER (2010)
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor-Positive Breast Cancer in Postmenopausal Women
Anita K. Dunbier et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen
Rikje Ruiter et al.
PHARMACOGENOMICS (2010)
CYP2C19*17 is associated with decreased breast cancer risk
Christina Justenhoven et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen
Masatsugu Okishiro et al.
CANCER (2009)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms
AJ Lee et al.
ENDOCRINOLOGY (2003)
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment
R Michalides et al.
BRITISH JOURNAL OF CANCER (2002)
The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers
WJ Tamminga et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Share Paper
